Information Provided By:
Fly News Breaks for February 6, 2018
MD
Feb 6, 2018 | 06:02 EDT
Jefferies analyst Brian Tanquilut believes upside in Mednax shares from current levels, even in a takeout, appears modest, at least for the next 12 months. Consensus expectations are "rational" but the stock is reflecting a takeover valuation, Tanquilut tells investors in a research note. The analyst raised his price target for Mednax to $50 from $44 and keeps a Hold rating on the name.
News For MD From the Last 2 Days
There are no results for your query MD